SCHEMBL2345314

SCHEMBL2345314

COc1cc(F)c(-n2c(Cl)nc(Cl)c2-c2cnc3ccccc3c2)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.38
PGK1 P00558 1/20 0.37
PDGFRB P09619 3/20 0.36
PDGFRA P16234 3/20 0.36
PIK3CD O00329 3/20 0.36
MTOR P42345 3/20 0.36
PIK3CB P42338 2/20 0.36
PIK3CG P48736 2/20 0.36
IGF1R P08069 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
CNR2 P34972 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MAPT P10636 1/20 0.35
CYP2A6 P11509 1/20 0.35
FPR1 P21462 1/20 0.35
FPR2 P25090 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2340013 0.90 PIK3CA (0.37) PIK3CAPGK1PDGFRBPDGFRAPIK3CD
SCHEMBL2340560 0.87 NPC1 (0.41) PIK3CAPDGFRBPDGFRAPIK3CDMTOR
SCHEMBL2451300 0.80 HTR3A (0.38) PIK3CAIGF1RCNR2NPC1RAB9A
SCHEMBL2345725 0.78 PIK3CA (0.41) PIK3CAPDGFRBPDGFRAPIK3CDMTOR
SCHEMBL2344399 0.73 PDE10A (0.34) FPR1FPR2
SCHEMBL121817 0.73 NPC1 (0.38) NPC1RAB9AMAPTFPR1FPR2
SCHEMBL2449304 0.72 CYP11B1 (0.38) PIK3CAPIK3CDMTORIGF1R
SCHEMBL1225560 0.69 MEN1 (0.39) NPC1RAB9AMAPTFPR2ALDH1A1
SCHEMBL2342861 0.69 MEN1 (0.35) PIK3CDNPC1RAB9ACYP2A6KDM4E
SCHEMBL2339990 0.68 KDM4E (0.50) MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224252-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2011-09-15 US claimed
EP-2201000-B1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2011-08-31 EP claimed
EP-2201000-A1 NOVEL IMIDAZOLE DERIVATIVES Syngenta Participations AG (CH) 2010-06-30 EP claimed
WO-2009053102-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2009-04-30 WO claimed
EP-2053045-A1 Novel imidazole derivatives Syngenta Participations AG (CH) 2009-04-29 EP claimed
US-20110224252-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2011-09-15 US disclosed
EP-2201000-B1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2011-08-31 EP disclosed
EP-2201000-A1 NOVEL IMIDAZOLE DERIVATIVES Syngenta Participations AG (CH) 2010-06-30 EP disclosed
WO-2009053102-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2009-04-30 WO disclosed
EP-2053045-A1 Novel imidazole derivatives Syngenta Participations AG (CH) 2009-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224252-A1 NOVEL IMIDAZOLE DERIVATIVES C1R, CBR3, C3AR1 PIK3CA 2929/4885PGK1 4583/4885PDGFRB 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.